Bacillus subtilis 1579 Polyphenol Conversion for PCA Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low bioavailability and inefficiency of dietary polyphenols, such as quercetin, limit their effectiveness in preventing diseases due to poor absorption and tissue distribution, necessitating a method to enhance their conversion to more bioavailable metabolites like protocatechuic acid (PCA) for improved health benefits.
Innovation Solution
Utilizing Bacillus subtilis 1579 or its active variants to convert polyphenols, particularly quercetin, into protocatechuic acid (PCA), which can be administered to humans or agricultural animals to decrease inflammation, cortisol levels, and increase milk quality and production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary polyphenols are administered directly, then health benefits are intended, but bioavailability is poor and absorption is limited
Solution Approach 1:
The patent applies preliminary action by pre-converting polyphenols into their metabolite forms (such as protocatechuic acid) before administration. The microbial composition is designed to perform the metabolic conversion in advance, so that when the metabolites are administered, they are already in the bioavailable form that can be effectively absorbed and utilized by the body, eliminating the need for the body to perform the conversion itself.
Solution Approach 2:
The patent uses microbial metabolites as intermediaries between dietary polyphenols and the body's absorption systems. The microbial composition acts as a mediator that transforms polyphenols into metabolite forms that serve as intermediate compounds, which are then more readily absorbed and distributed to tissues, bridging the gap between polyphenol ingestion and effective utilization.
2Reliability
If exogenous protocatechuic acid is supplemented, then health benefits are provided, but cost increases and storage efficacy is reduced
Solution Approach 1:
The patent applies self-service by enabling the body's own microbial flora to produce the beneficial metabolites from dietary polyphenols. Instead of requiring external supplementation with protocatechuic acid, the microbial composition empowers the body to generate its own supply of these metabolites through the conversion of polyphenols, eliminating the need for costly exogenous supplementation and associated storage concerns.
3Quantity of substance
If polyphenols are ingested in higher concentrations, then potential health benefits increase, but absorption efficiency remains poor and tissue distribution is uneven
Solution Approach 1:
The patent applies parameter changes by transforming polyphenols into metabolite forms with different chemical and physical properties. This transformation changes parameters such as molecular size, solubility, and stability, which collectively improve absorption efficiency and tissue distribution. The metabolites are more readily absorbed across intestinal barriers and distributed more evenly to target tissues compared to the parent polyphenol compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conversion process enhances the bioavailability of polyphenols, reducing inflammation and cortisol levels while increasing milk quality and quantity in milk-producing animals, offering a cost-effective and efficient alternative to exogenous supplementation.
Implementation Method 1
Bacillus subtilis 1579 or active variants thereof to convert polyphenols, particularly quercetin, into protocatechuic acid (PCA)
Data Source
AI summary
Compositions and methods for converting at least one polyphenol to protocatechuic acid (PCA) using Bacillus subtilis 1579, or active variants thereof, are provided. Conversion of polyphenols, such as quercetin, to PCA can decrease inflammation, decrease cortisol levels, and increase milk quality and milk production quantity in milk-producing agricultural animals. Accordingly, provided herein are compositions comprising B. subtilis 1579, or an active variant thereof, for administration to humans for decreasing inflammation or for administration to milk-producing agricultural animals for decreasing inflammation, decreasing cortisol levels, and increasing milk quality and milk production.